Eluxadoline
Skeletal structure of eluxadoline | |
Ball-and-stick model of eluxadoline | |
| Clinical data | |
|---|---|
| Pronunciation | Viberzi (/vaɪˈbɜːrzi/ vy-BUR-zee |
| Trade names | Viberzi, Truberzi |
| Other names | JNJ-27018966 |
| Addiction liability | None |
| Routes of administration | Oral (by mouth) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 1.0 % (low due to poor gastrointestinal permeability and significant first-pass metabolism) |
| Protein binding | 81% |
| Elimination half-life | 3.7–6 hours |
| Excretion | 82.2% (feces), <1% (urine) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C32H35N5O5 |
| Molar mass | 569.662 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Eluxadoline, sold under the brand names Viberzi and Truberzi, is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.